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SIRS, We thank Dr Hawkey for his interest in our article1, 2
and agree with some of his comments concerning the limi-
tations of the study. In our article2 and in the original pub-
lication of the CONDOR trial,3 we clearly stated that the
most frequent outcome event was a decrease in haemoglo-
bin (Hb) 2g/dL of presumed small bowel origin. The adju-
dication of the events was based on a rigorous protocol,
where investigators blinded to treatment excluded other
potential sources of a Hb drop, including ongoing inflam-
matory, renal, cardiac or haematological conditions.
We acknowledged the lack of direct evidence for the
presence of bleeding lesions beyond the duodenum in
most cases of Hb decrease without nongastrointestinal
reasons, and that is why those events were reported as
‘of presumed small bowel origin’ with tempered conclu-
sions. Although we agree that suppression of haemato-
poiesis by chronic inflammation may explain some of
the Hb decrease seen in our study, we have no evidence
of baseline differences in the osteoarthritis (OA) popula-
tion between the two arms of our study, and we are not
aware that celecoxib should have a different effect on ha-
ematopoiesis or chronic inflammation than diclofenac in
our OA patients that could explain the differences
between the two arms.3
On the contrary, there is considerable evidence that tra-
ditional nonsteroidal anti-inflammatory drugs (NSAIDs)
induce small bowel lesions more often than celecoxib4, 5
and that occult blood loss in the GI tract is more common
with NSAIDs than coxib use.6 All of these facts support
the plausibility of our conclusions.
We believe that small bowel lesions associated with
NSAID use have clinical relevance and that this is a new
area of interest. Our study is an early foray in this field,
and further studies should confirm and better define the
risk factors and mechanisms beyond the Hb decrease
associated with NSAID use, including those linking Hb
decreases in OA patients with additional tests looking
for the presence of lesions in the upper and lower gas-
trointestinal tract.
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